Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ligufalimab by Akeso for Myelodysplastic Syndrome: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Akeso's Ligufalimab?
Ligufalimab is a monoclonal antibody commercialized by Akeso, with a leading Phase II program in Colorectal Cancer. According to Globaldata,...
Ligufalimab by Akeso for Non-Hodgkin Lymphoma: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...
Ligufalimab by Akeso for Lymphoma: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs...
Ligufalimab by Akeso for Solid Tumor: Likelihood of Approval
Ligufalimab is under clinical development by Akeso and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...